{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:29:47Z","timestamp":1790112587076,"version":"4.0.1"},"reference-count":140,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>For those born with cystic fibrosis (CF), hyper-concentrated mucus with a dysfunctional structure significantly impacts CF airways, providing a perfect environment for bacterial colonization and subsequent chronic infection. Early treatment with antibiotics limits the prevalence of bacterial pathogens but permanently alters the CF airway microenvironment, resulting in antibiotic resistance and other long-term consequences. With little investment into new traditional antibiotics, safe and effective alternative therapeutic options are urgently needed. One gathering significant traction is bacteriophage (phage) therapy. However, little is known about which phages are effective for respiratory infections, the dynamics involved between phage(s) and the host airway, and associated by-products, including mucus. Work utilizing gut cell models suggest that phages adhere to mucus components, reducing microbial colonization and providing non-host-derived immune protection. Thus, phages retained in the CF mucus layer result from the positive selection that enables them to remain in the mucus layer. Phages bind weakly to mucus components, slowing down the diffusion motion and increasing their chance of encountering bacterial species for subsequent infection. Adherence of phage to mucus could also facilitate phage enrichment and persistence within the microenvironment, resulting in a potent phage phenotype or vice versa. However, how the CF microenvironment responds to phage and impacts phage functionality remains unknown. This review discusses CF associated lung diseases, the impact of CF mucus, and chronic bacterial infection. It then discusses the therapeutic potential of phages, their dynamic relationship with mucus and whether this may enhance or hinder airway bacterial infections in CF.<\/jats:p>","DOI":"10.3389\/fmed.2023.1088494","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T05:40:26Z","timestamp":1684302026000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Pulmonary bacteriophage and cystic fibrosis airway mucus: friends or foes?"],"prefix":"10.3389","volume":"10","author":[{"given":"Kak-Ming","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Michael","family":"Stick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Kicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"ref1","author":"O\u2019Neil","year":"2014"},{"key":"ref2","author":"Anitha","year":"2021"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jcf.2018.12.004","article-title":"Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis","volume":"18","author":"Flume","year":"2019","journal-title":"J Cyst Fibros"},{"key":"ref4","first-page":"1","article-title":"Phage therapy pharmacology. Phage cocktails","volume-title":"Advances in applied microbiology","author":"Chan","year":"2012"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/14787210.2022.1990755","article-title":"Phage therapy in pediatrics: the way forward for difficult-to-treat infections?","volume":"20","author":"Howard-Jones","year":"2022","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1002\/ppul.25190","article-title":"Bacteriophage therapy for infections in CF","volume":"56","author":"Chan","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.3389\/fphar.2018.01330","article-title":"Use of a primary epithelial cell screening tool to investigate phage therapy in cystic fibrosis","volume":"9","author":"Trend","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3389\/fmicb.2014.00599","article-title":"Temperature dependent bacteriophages of a tropical bacterial pathogen","volume":"5","author":"Shan","year":"2014","journal-title":"Front Microbiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nature21049","article-title":"Communication between viruses guides lysis\u2013lysogeny decisions","volume":"541","author":"Erez","year":"2017","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4161\/bact.1.1.14942","article-title":"Phages in nature","volume":"1","author":"Clokie","year":"2011","journal-title":"Bacteriophage"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e2116197119","DOI":"10.2139\/ssrn.3871902","article-title":"Bacteriophages evolve enhanced persistence to a mucosal surface","volume":"119","author":"Chin","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.medmal.2008.06.023","article-title":"Phage therapy experience at the Eliava institute","volume":"38","author":"Kutateladze","year":"2008","journal-title":"Med Mal Infect"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1111\/ajt.15503","article-title":"Early clinical experience of bacteriophage therapy in 3 lung transplant recipients","volume":"19","author":"Aslam","year":"2019","journal-title":"Am J Transplant"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/S15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.1751-7915.2011.00259.x","article-title":"Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens","volume":"4","author":"Kvachadze","year":"2011","journal-title":"Microb Biotechnol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"eaav3488","DOI":"10.1126\/scitranslmed.aav3488","article-title":"Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis","volume":"11","author":"Esther","year":"2019","journal-title":"Sci Transl Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e1006798","DOI":"10.1371\/journal.ppat.1006798","article-title":"Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children","volume":"14","author":"Muhlebach","year":"2018","journal-title":"PLoS Pathog"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1183\/09059180.00006113","article-title":"Current concepts: host-pathogen interactions in cystic fibrosis airways disease","volume":"23","author":"Tang","year":"2014","journal-title":"Eur Respir Rev"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1126\/science.7543698","article-title":"CFTR as a cAMP-dependent regulator of sodium channels","volume":"269","author":"Stutts","year":"1995","journal-title":"Science"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1164\/rccm.200403-381WS","article-title":"Macromolecular interactions and ion transport in cystic fibrosis","volume":"170","author":"Guggino","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"32227","DOI":"10.1074\/jbc.M110.155259","article-title":"The cystic fibrosis transmembrane conductance regulator impedes proteolytic stimulation of the epithelial Na+ channel","volume":"285","author":"Gentzsch","year":"2010","journal-title":"J Biol Chem"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/B978-0-12-404577-4.00029-1","article-title":"Mucociliary function","volume-title":"Comparative biology of the Normal lung","author":"Foster","year":"2015"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/nejm198112173052502","article-title":"Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis","volume":"305","author":"Knowles","year":"1981","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0092-8674(00)81724-9","article-title":"Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease","volume":"95","author":"Matsui","year":"1998","journal-title":"Cells"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00431-008-0693-2","article-title":"What\u2019s new in cystic fibrosis? From treating symptoms to correction of the basic defect","volume":"167","author":"Proesmans","year":"2008","journal-title":"Eur J Pediatr"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1126\/science.1223012","article-title":"A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia","volume":"337","author":"Button","year":"2012","journal-title":"Science"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1021\/ja803925n","article-title":"Cationic amphiphiles increase activity of aminoglycoside antibiotic tobramycin in the presence of airway polyelectrolytes","volume":"131","author":"Drew","year":"2009","journal-title":"J Am Chem Soc"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ijpharm.2017.09.018","article-title":"Physicochemical properties of mucus and their impact on transmucosal drug delivery","volume":"532","author":"Leal","year":"2017","journal-title":"Int J Pharm"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/jac\/dkp165","article-title":"Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa","volume":"64","author":"Alipour","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1164\/ARRD.1985.132.4.761","article-title":"Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum","volume":"132","author":"Mendelman","year":"1985","journal-title":"Am Rev Respir Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/17425255.2021.1836157","article-title":"The pharmacokinetics of antibiotics in cystic fibrosis","volume":"17","author":"Akkerman-Nijland","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/thx.2007.082388","article-title":"Neutrophils in cystic fibrosis","volume":"64","author":"Downey","year":"2009","journal-title":"Thorax"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1164\/rccm.201011-1892OC","article-title":"Infection, inflammation, and lung function decline in infants with cystic fibrosis","volume":"184","author":"Pillarisetti","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis","volume":"368","author":"Sly","year":"2013","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1164\/rccm.201810-1919OC","article-title":"Changing prevalence of lower airway infections in young children with cystic fibrosis","volume":"200","author":"Breuer","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1183\/09059180.00006512","article-title":"Treatment of pulmonary exacerbations in cystic fibrosis","volume":"22","author":"Bhatt","year":"2013","journal-title":"Eur Respir Rev"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1164\/rccm.200309-1306oc","article-title":"Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa","volume":"169","author":"Aaron","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/ppul.20220","article-title":"How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?","volume":"39","author":"VanDevanter","year":"2005","journal-title":"Pediatr Pulmonol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jcf.2011.05.002","article-title":"Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?","volume":"10","author":"Stressmann","year":"2011","journal-title":"J Cyst Fibros"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3389\/fcimb.2017.00104","article-title":"Understanding the entanglement: neutrophil extracellular traps (NETs) in cystic fibrosis","volume":"7","author":"Mart\u00ednez-Alem\u00e1n","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/adc.84.2.160","article-title":"Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis","volume":"84","author":"Miall","year":"2001","journal-title":"Arch Dis Child"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0140-6736(14)61137-5","article-title":"Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis","volume":"384","author":"Sherrard","year":"2014","journal-title":"Lancet"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X20155097","article-title":"Clinical impact of Achromobacter xylosoxidans colonization\/infection in patients with cystic fibrosis","volume":"49","author":"Firmida","year":"2016","journal-title":"Braz J Med Biol Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s40506-016-0092-6","article-title":"Nontuberculous mycobacteria in cystic fibrosis","volume":"8","author":"Skolnik","year":"2016","journal-title":"Curr Treat Options Infect Dis"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/ppul.23781","article-title":"Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosis","volume":"52","author":"Barsky","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1016\/j.xphs.2017.06.010","article-title":"Population pharmacokinetics of tobramycin inhalation solution in pediatric patients with cystic fibrosis","volume":"106","author":"Wang","year":"2017","journal-title":"J Pharm Sci"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/antibiotics10030338","article-title":"Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives","volume":"10","author":"Taccetti","year":"2021","journal-title":"Antibiotics"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jcf.2016.09.002","article-title":"Continuous alternating inhaled antibiotic therapy in CF: a single center retrospective analysis","volume":"15","author":"Van de Kerkhove","year":"2016","journal-title":"J Cyst Fibros"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jgar.2021.12.008","article-title":"Ceftaroline versus vancomycin for treatment of acute pulmonary exacerbations of cystic fibrosis in adults","volume":"28","author":"Esquivel","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e000956","DOI":"10.1136\/bmjresp-2021-000956","article-title":"Variation in treatment preferences of pulmonary exacerbations among Australian and New Zealand cystic fibrosis physicians","volume":"8","author":"Currie","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"18131","DOI":"10.1073\/pnas.0606428103","article-title":"A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms","volume":"103","author":"Matsui","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e37375","DOI":"10.1371\/journal.pone.0037375","article-title":"Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome","volume":"7","author":"Samonis","year":"2012","journal-title":"PLoS One"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1586\/17476348.2015.995640","article-title":"The problems of antibiotic resistance in cystic fibrosis and solutions","volume":"9","author":"L\u00f3pez-Causap\u00e9","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1128\/AEM.02850-14","article-title":"Burkholderia cepacia complex phage-antibiotic synergy (PAS): antibiotics stimulate lytic phage activity","volume":"81","author":"Kamal","year":"2015","journal-title":"Appl Environ Microbiol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00705-018-3811-0","article-title":"Piperacillin and ceftazidime produce the strongest synergistic phage\u2013antibiotic effect in Pseudomonas aeruginosa","volume":"163","author":"Uchiyama","year":"2018","journal-title":"Arch Virol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01025-20","article-title":"Achromobacter infections and treatment options","volume":"64","author":"Isler","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/S41522-017-0035-0","article-title":"Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance","volume":"3","author":"Beaudoin","year":"2017","journal-title":"NPJ Biofilms Microbio"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1128\/AAC.45.3.781-785.2001","article-title":"In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis","volume":"45","author":"Li","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jcf.2008.02.003","article-title":"Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients","volume":"7","author":"Johansen","year":"2008","journal-title":"J Cyst Fibros"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","article-title":"Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing","volume":"30","author":"Lim","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1128\/AAC.05829-11","article-title":"PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients","volume":"56","author":"Moskowitz","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref64","article-title":"Registry on behalf of the ACFD. The Australian Cystic Fibrosis Data Registry Annual Report 2020","author":"Ahern","year":"2021"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1513\/ANNALSATS.201402-050AS\/SUPPL_FILE\/DISCLOSURES.PDF","article-title":"Antibiotic management of lung infections in cystic fibrosis: I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections","volume":"11","author":"Chmiel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3390\/V13071331","article-title":"Advances in Phage Therapy: Targeting the Burkholderia cepacia Complex","volume":"13","author":"Lauman","year":"2021","journal-title":"Viruses"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3122\/jabfm.2020.06.200210","article-title":"Educating patients on unnecessary antibiotics: personalizing potential harm aids patient understanding","volume":"33","author":"Miller","year":"2020","journal-title":"J Am Board Fam Med"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9091874","article-title":"Current and emerging therapies to combat cystic fibrosis lung infections","volume":"9","author":"Manos","year":"2021","journal-title":"Microorganisms"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1128\/AAC.00045-11","article-title":"Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo","volume":"55","author":"Brackman","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"17981","DOI":"10.1073\/pnas.1316981110","article-title":"A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation","volume":"110","author":"O\u2019Loughlin","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1165\/rcmb.2008-0299OC","article-title":"Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells","volume":"41","author":"Moreau-Marquis","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.3389\/fmicb.2018.01811","article-title":"Novel iron-chelator DIBI inhibits Staphylococcus aureus growth, suppresses experimental MRSA infection in mice and enhances the activities of diverse antibiotics in vitro","volume":"9","author":"Kirienko","year":"2018","journal-title":"Front Microbiol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1021\/jm400262a","article-title":"Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance","volume":"56","author":"Sabatini","year":"2013","journal-title":"J Med Chem"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.3389\/fmicb.2018.02990","article-title":"Inhibiting bacterial drug efflux pumps via phyto-therapeutics to combat threatening antimicrobial resistance","volume":"9","author":"Shriram","year":"2018","journal-title":"Front Microbiol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ijpharm.2013.05.041","article-title":"A peptide-morpholino oligomer conjugate targeting Staphylococcus aureus gyrA mRNA improves healing in an infected mouse cutaneous wound model","volume":"453","author":"Sawyer","year":"2013","journal-title":"Int J Pharm"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/infdis\/jit460","article-title":"Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo","volume":"208","author":"Geller","year":"2013","journal-title":"J Infect Dis"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.chembiol.2018.05.019","article-title":"Synthetic immunotherapeutics against Gram-negative pathogens","volume":"25","author":"Feigman","year":"2018","journal-title":"Cell Chem Biol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1128\/IAI.00318-08","article-title":"Human host defense peptide LL-37 prevents bacterial biofilm formation","volume":"76","author":"Overhage","year":"2008","journal-title":"Infect Immun"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12929-020-00678-3","article-title":"A synthetic peptide sensitizes multi-drug resistant Pseudomonas aeruginosa to antibiotics for more than two hours and permeabilizes its envelope for twenty hours","volume":"27","author":"R\u00e1zquin-Olazar\u00e1n","year":"2020","journal-title":"J Biomed Sci"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3111\/13696998.2011.638954","article-title":"Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"15","author":"Sansgiry","year":"2011","journal-title":"J Med Econ"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1086\/648478","article-title":"Bacteriophage therapy of Salmonella enterica: a fresh appraisal of bacteriophage therapy","volume":"201","author":"Capparelli","year":"2010","journal-title":"J Infect Dis"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.virol.2012.09.002","article-title":"Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh","volume":"434","author":"Sarker","year":"2012","journal-title":"Virology"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1128\/AAC.06330-11","article-title":"Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b: H4-ST131 Escherichia coli strain producing CTX-M-15","volume":"56","author":"Pouillot","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0065-2164(10)70007-1","article-title":"Bacteriophage host range and bacterial resistance","volume-title":"Advances in applied microbiology","author":"Hyman","year":"2010"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-23418-y","article-title":"Bacteriophages are more virulent to bacteria with human cells than they are in bacterial culture; insights from HT-29 cells","volume":"8","author":"Shan","year":"2018","journal-title":"Sci Rep"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41564-019-0634-z","article-title":"Safety of bacteriophage therapy in severe Staphylococcus aureus infection","volume":"5","author":"Petrovic Fabijan","year":"2020","journal-title":"Nat Microbiol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciac453","article-title":"Phage therapy of mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease","volume":"76","author":"Dedrick","year":"2023","journal-title":"Clin Infect Dis"},{"key":"ref88","year":"2023"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2017.09.023","article-title":"The biology of mucus: composition, synthesis and organization","volume":"124","author":"Bansil","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.cell.2006.08.019","article-title":"Glycosylation in cellular mechanisms of health and disease","volume":"126","author":"Ohtsubo","year":"2006","journal-title":"Cells"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.sbi.2016.09.013","article-title":"Multi-level regulation of cellular glycosylation: from genes to transcript to enzyme to structure","volume":"40","author":"Neelamegham","year":"2016","journal-title":"Curr Opin Struct Biol"},{"key":"ref92","author":"Ling","year":"2021"},{"key":"ref93","first-page":"139","article-title":"Cellular and molecular biology of airway mucins","volume-title":"International review of cell and molecular biology","author":"Lillehoj","year":"2013"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jcf.2022.04.008","article-title":"Mucus and mucus flake composition and abundance reflect inflammatory and infection status in cystic fibrosis","volume":"21","author":"Markovetz","year":"2022","journal-title":"J Cyst Fibros"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1086\/651135","article-title":"Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections","volume":"201","author":"Debarbieux","year":"2010","journal-title":"J Infect Dis"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/thoraxjnl-2016-209265","article-title":"Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa","volume":"72","author":"Waters","year":"2017","journal-title":"Thorax"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"e956","DOI":"10.1016\/S2666-5247(22)00288-9","article-title":"Efficacy of phage therapy in preclinical models of bacterial infection: a systematic review and meta-analysis","volume":"3","author":"G\u00f3mez-Ochoa","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejpb.2020.11.019","article-title":"Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation\u2014a proof-of-principle study in a P. aeruginosa lung infection model","volume":"158","author":"Lin","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.coviro.2022.101290","article-title":"The role of the animal host in the management of bacteriophage resistance during phage therapy","volume":"58","author":"Gaborieau","year":"2023","journal-title":"Curr Opin Virol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110825","article-title":"Combination of in vivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacy","volume":"39","author":"Delattre","year":"2022","journal-title":"Cell Rep"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nm1028","article-title":"Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice","volume":"10","author":"Mall","year":"2004","journal-title":"Nat Med"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"29ra31","DOI":"10.1126\/scitranslmed.3000928","article-title":"Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth","volume":"2","author":"Stoltz","year":"2010","journal-title":"Sci Transl Med"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1165\/rcmb.2013-0261OC","article-title":"Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulator\u2013knockout ferrets","volume":"50","author":"Sun","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"e91253","DOI":"10.1371\/journal.pone.0091253","article-title":"Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats","volume":"9","author":"Tuggle","year":"2014","journal-title":"PLoS One"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.ajpath.2020.01.009","article-title":"Phenotypic characterization and comparison of cystic fibrosis rat models generated using CRISPR\/Cas9 gene editing","volume":"190","author":"McCarron","year":"2020","journal-title":"Am J Pathol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3389\/fphar.2018.01475","article-title":"Animal models in the pathophysiology of cystic fibrosis","volume":"9","author":"Semaniakou","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.3389\/fmicb.2020.593988","article-title":"Overcoming challenges to make bacteriophage therapy standard clinical treatment practice for cystic fibrosis","volume":"11","author":"Ng","year":"2021","journal-title":"Front Microbiol"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.3389\/fphar.2018.01330","article-title":"Use of a primary epithelial cell screening tool to investigate phage therapy in cystic fibrosis","volume":"9","author":"Trend","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.tox.2010.04.004","article-title":"Human primary bronchial lung cell constructs: the new respiratory models","volume":"278","author":"B\u00e9ruB\u00e9","year":"2010","journal-title":"Toxicology"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00256.2010","article-title":"The air-liquid interface and use of primary cell cultures are important to recapitulate the transcriptional profile of in vivo airway epithelia","volume":"300","author":"Pezzulo","year":"2011","journal-title":"Am J Phys Lung Cell Mol Phys"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.addr.2014.11.017","article-title":"Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients","volume":"85","author":"Ciofu","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1128\/AEM.70.6.3417-3424.2004","article-title":"Evaluation of a cocktail of three bacteriophages for biocontrol of Escherichia coli O157:H7","volume":"70","author":"O\u2019Flynn","year":"2004","journal-title":"Appl Environ Microbiol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.01462-20","article-title":"Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry","volume":"11","author":"Liu","year":"2020","journal-title":"MBio"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/emph\/eoy005","article-title":"Phage treatment of an aortic graft infected with Pseudomonas aeruginosa","volume":"2018","author":"Chan","year":"2018","journal-title":"Evol Med Public Health"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-27656-z","article-title":"Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae","volume":"13","author":"Eskenazi","year":"2022","journal-title":"Nat Commun"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/cid\/ciz222","article-title":"Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination","volume":"69","author":"Nir-Paz","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-1097(04)00041-2","article-title":"The interaction of phage and biofilms","volume":"232","author":"Sutherland","year":"2004","journal-title":"FEMS Microbiol Lett"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/antibiotics3030270","article-title":"Bacteriophages and biofilms","volume":"3","author":"Harper","year":"2014","journal-title":"Antibiotics"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"198496","DOI":"10.1016\/j.virusres.2021.198496","article-title":"Bacteriophage cocktail and phage antibiotic synergism as promising alternatives to conventional antibiotics for the control of multi-drug-resistant uropathogenic Escherichia coli","volume":"302","author":"Malik","year":"2021","journal-title":"Virus Res"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41564-017-0061-y","article-title":"Pseudomonas aeruginosa defends against phages through type IV pilus glycosylation","volume":"3","author":"Harvey","year":"2017","journal-title":"Nat Microbiol"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"11207","DOI":"10.1073\/pnas.1919888117","article-title":"Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance","volume":"117","author":"Burmeister","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41586-019-1894-8","article-title":"The arms race between bacteria and their phage foes","volume":"577","author":"Hampton","year":"2020","journal-title":"Nature"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41564-017-0051-0","article-title":"DISARM is a widespread bacterial defence system with broad anti-phage activities","volume":"3","author":"Ofir","year":"2017","journal-title":"Nat Microbiol"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3390\/v13071268","article-title":"The safety and toxicity of phage therapy: a review of animal and clinical studies","volume":"13","author":"Liu","year":"2021","journal-title":"Viruses"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1093\/NAR\/GKT1419","article-title":"A widespread bacteriophage abortive infection system functions through a type IV toxin-antitoxin mechanism","volume":"42","author":"Dy","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev-virology-011620-040628","article-title":"Abortive infection: bacterial suicide as an antiviral immune strategy","volume":"7","author":"Lopatina","year":"2020","journal-title":"Annu Rev Virol"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-31330-3","article-title":"Mucin induces CRISPR-Cas defense in an opportunistic pathogen","volume":"13","author":"de Freitas Almeida","year":"2022","journal-title":"Nat Commun"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.diagmicrobio.2009.09.009","article-title":"Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients","volume":"66","author":"King","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"e7370","DOI":"10.1371\/journal.pone.0007370","article-title":"Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and non-cystic fibrosis individuals","volume":"4","author":"Willner","year":"2009","journal-title":"PLoS One"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.sbi.2015.07.006","article-title":"Exploring the interactions between bacteriophage-encoded glycan binding proteins and carbohydrates","volume":"34","author":"Simpson","year":"2015","journal-title":"Curr Opin Struct Biol"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"10771","DOI":"10.1073\/pnas.1305923110","article-title":"Bacteriophage adhering to mucus provide a non-host-derived immunity","volume":"110","author":"Barr","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.03474-20","article-title":"Targeting of mammalian glycans enhances phage predation in the gastrointestinal tract","volume":"12","author":"Green","year":"2021","journal-title":"MBio"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01984-19","article-title":"Bacteriophage adherence to mucus mediates preventive protection against pathogenic bacteria","volume":"10","author":"Almeida","year":"2019","journal-title":"MBio"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1128\/AEM.00542-15","article-title":"Coral mucus is a hot spot for viral infections","volume":"81","author":"Nguyen-Kim","year":"2015","journal-title":"Appl Environ Microbiol"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"13675","DOI":"10.1073\/pnas.1508355112","article-title":"Subdiffusive motion of bacteriophage in mucosal surfaces increases the frequency of bacterial encounters","volume":"112","author":"Barr","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.03474-20","article-title":"Targeting of mammalian Glycans enhances phage predation in the gastrointestinal tract","volume":"12","author":"Green","year":"2021","journal-title":"MBio"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/s41564-019-0581-8","article-title":"Mucin glycans attenuate the virulence of Pseudomonas aeruginosa in infection introductory paragraph","volume":"4","author":"Wheeler","year":"2019","journal-title":"Nat Microbiol"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"2022.05.26.493615","DOI":"10.1101\/2022.05.26.493615","article-title":"Pseudomonas aeruginosa contracts mucus to rapidly form biofilms in tissue-engineered human airways","author":"Rossy","year":"2022","journal-title":"bioRxiv"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1021\/acsbiomaterials.8b01054","article-title":"Mucus and mucin environments reduce the efficacy of polymyxin and fluoroquinolone antibiotics against Pseudomonas aeruginosa","volume":"5","author":"Samad","year":"2019","journal-title":"ACS Biomater Sci Eng"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00773-20","article-title":"A novel group of promiscuous podophages infecting diverse gammaproteobacteria from river communities exhibits dynamic intergenus host adaptation","volume":"6","author":"Cazares","year":"2021","journal-title":"mSystems"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1088494\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T05:40:35Z","timestamp":1684302035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1088494\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":140,"alternative-id":["10.3389\/fmed.2023.1088494"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1088494","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"article-number":"1088494"}}